Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2003
10/16/2003US20030195168 Comprises macrocyclic diterpene compounds from Euphorbiaceae for treatment and prophylaxis of protein kinase C (PKC) related conditions (alcoholism, Alzheimer's disease, asthma, atherosclerosis); expression inhibition; computer programs
10/16/2003US20030195157 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
10/16/2003US20030195140 Methods and compositions for improving sleep
10/16/2003US20030195139 For treating subject with abstinence syndrome due to nicotine, an opiate, cocaine, an amphetamine, a benzodiazipine and ethanol
10/16/2003US20030194761 Novel nucleic acid sequences encoding human fibroblast growth factor-like polypeptides
10/16/2003US20030194742 Diagnosis of tauopathies
10/16/2003US20030194732 For treating neoplastic diseases by testing responsiveness to interferons
10/16/2003US20030194729 Conantokins
10/16/2003US20030194720 Human ion channels
10/16/2003US20030194719 Tpst-assay for diagnosis of autism and related disorders
10/16/2003US20030194439 Pharmaceutical dosage form for pulsatile delivery of methylphenidate
10/16/2003US20030194413 Methods and compositions employing red rice fermentation products
10/16/2003US20030194398 Having serine protease inhibitory activity
10/16/2003US20030194397 Introducing platelet-rich plasma into and around the site of the injury
10/16/2003US20030194375 Anti-epileptogenic agents
10/16/2003CA2708900A1 Pharmaceutical preparation containing oxycodone and naloxone
10/16/2003CA2694410A1 Pyridinoylpiperidines as 5-ht1f agonists
10/16/2003CA2486480A1 Improved kavalactone profile
10/16/2003CA2481995A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
10/16/2003CA2481976A1 Novel thyroid receptor ligands
10/16/2003CA2481970A1 Neurotrophic factor production accelerator
10/16/2003CA2481879A1 Hydroxamic acid derivatives
10/16/2003CA2481850A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
10/16/2003CA2481701A1 Benzoxazinone-derived compounds, their preparation and use as medicaments
10/16/2003CA2481514A1 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
10/16/2003CA2481392A1 Terphenyl derivatives, preparation thereof, compositions containing same
10/16/2003CA2481035A1 (2-((2-alkoxy) -phenyl) -cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives
10/16/2003CA2481028A1 Hormone replacement therapy
10/16/2003CA2481026A1 N-`4-(2-imino-pyrrolidin-1-yl)phenyl!-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases
10/16/2003CA2480818A1 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003CA2480692A1 Chemokines mutants having improved oral bioavailability
10/16/2003CA2480311A1 Oligomeric compounds for the modulation of hif-1alpha expression
10/16/2003CA2480082A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
10/16/2003CA2478934A1 Process for producing oil and fat composition containing hydrophobic components of glycyrrhiza
10/16/2003CA2478523A1 Matrix for sustained, invariant and independent release of active compounds
10/16/2003CA2478227A1 Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
10/16/2003CA2477943A1 Heterocyclic amides with alpha-4 integrin antagonist activity
10/16/2003CA2462708A1 Diazabicyclo alkane derivatives with nk1 antagonistic activity
10/15/2003EP1352910A1 New analogs of nitrobenzylthioinosine
10/15/2003EP1352897A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352896A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352895A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352659A1 Combination drugs
10/15/2003EP1352653A1 Dihydrofuran cyclic tanshintones used in treating hyperammonemia and hepatic encephalopathy
10/15/2003EP1352651A2 Novel use of orexin receptor antagonists
10/15/2003EP1352647A1 Controlled-release sedative hypnotic compositions and method related thereto
10/15/2003EP1352084A2 Method for identifying modulators of bace
10/15/2003EP1352077A2 Materials and methods relating to protein aggregation in neurodegenerative disease
10/15/2003EP1352073A2 Electrically responsive promoter system
10/15/2003EP1352063A2 Receptor nucleic acids and polypeptides
10/15/2003EP1352061A2 Method for inhibiting the expression of a target gene
10/15/2003EP1351985A2 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors
10/15/2003EP1351980A2 Peptides for activation and inhibition of delta pkc
10/15/2003EP1351976A2 Gpe analogs
10/15/2003EP1351975A2 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
10/15/2003EP1351968A1 Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus
10/15/2003EP1351961A1 Substituted indolines as 5-ht receptor ligands
10/15/2003EP1351956A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors
10/15/2003EP1351955A1 Excitatory amino acid receptor antagonists
10/15/2003EP1351953A1 Quinoline derivatives as nk-3 antagonists
10/15/2003EP1351952A2 Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
10/15/2003EP1351951A2 Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
10/15/2003EP1351950A2 Isoindolyl and isoquinolinyl aroyl pyrrole compounds for the treatment of central nervous system disorders
10/15/2003EP1351942A1 Novel 2,3-benzodiazepine derivatives and pharmaceutical compositions containing the same as the active ingredient
10/15/2003EP1351934A1 Naphthalene derivatives which bind to the ep4 receptor
10/15/2003EP1351933A1 Il-8 receptor antagonists
10/15/2003EP1351929A1 Nitric oxide synthase inhibitor phosphate salt
10/15/2003EP1351928A2 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use
10/15/2003EP1351925A1 Prodrugs of excitatory amino acids
10/15/2003EP1351916A2 Ether compounds and compositions for cholesterol management and related uses
10/15/2003EP1351707A2 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
10/15/2003EP1351694A1 Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent
10/15/2003EP1351690A2 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance
10/15/2003EP1351688A1 Urotensin-ii receptor antagonists
10/15/2003EP1351687A2 Urotensin-ii receptor antagonists
10/15/2003EP1351684A2 Compounds and methods for promoting smoking cessation
10/15/2003EP1351683A2 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
10/15/2003EP1351679A2 Method and composition for the treatment of diabetic neuropathy
10/15/2003EP1351672A1 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
10/15/2003EP1351670A1 Methods for treating neuropsychiatric disorders with nmda receptor antagonists
10/15/2003EP1351668A1 Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles
10/15/2003EP1351667A1 Pharmaceutical composition containing citalopram
10/15/2003EP1351648A2 Carrier vectors through an epithelium with tight junctions
10/15/2003EP1268471B1 N-heterocyclic derivatives as nos inhibitors
10/15/2003EP1259508B1 Novel biarylcarboxamides
10/15/2003EP1246799B1 Substituted pyrrole mannich bases to combat pain and allergic reactions
10/15/2003EP1233758B1 Sodium valproate granulate with reduced hygroscopicity
10/15/2003EP1228041B1 Indole derivatives and their use as 5ht2a ligands
10/15/2003EP1206457B1 Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
10/15/2003EP1183037B1 Compositions for modulating immune response and for the treatment of inflammatory disease
10/15/2003EP1140929B1 1h-imidazo 4,5-d]pyridazin-7-ones, 3h-imidazo 4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (crf) receptor ligands
10/15/2003EP0977757B1 9,10-diazatricyclo 4.2.1.1?2,5 ]decane and 9,10-diazatricyclo 3.3.1.1?2,6 ]decane derivatives having analgesic activity
10/15/2003EP0950047B1 Indolin-2-one derivatives, method for preparing them and pharmaceutical compositions containing them
10/15/2003EP0861246B1 Prolyl endopeptidase inhibitors, their preparation and their pharmaceutical use
10/15/2003EP0855391B1 Novel isoquinoline derivatives
10/15/2003EP0763032B1 Palladium catalyzed ring closure of triazolyl tryptamine
10/15/2003CN1449493A Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
10/15/2003CN1449448A 干细胞分化 Stem cell differentiation
10/15/2003CN1449439A Cell fraction containing cells capable of differentiating into nervous system cells
10/15/2003CN1449410A Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
1 ... 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 ... 1833